Insights
Search Results
Client Highlights
5.20.25
Firm Advises Sirius on Patent Matters Related to CRISPR Therapeutics Collaboration
On May 20, 2025, CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, announced a strategic partnership to develop and commercialize novel siRNA therapies. Wilson Sonsini Goodrich & Rosati advised Sirius on patent matters related to the transaction.
Under the terms of the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to Sirius. The companies will jointly develop SRSD107—a next-generation, long-acting Factor XI (FXI) siRNA for the treatment of thromboembolic disorders—under a 50-50 cost and profit-sharing structure. CRISPR Therapeutics will lead commercialization in the U.S., while Sirius will be responsible for commercialization in Greater China. Additionally, CRISPR Therapeutics will have the option to nominate up to two siRNA targets for research and development. For each target, CRISPR Therapeutics will fund research and retain opt-in rights to lead clinical development and commercialization. Sirius will be eligible to receive milestone payments, as well as tiered royalties ranging from high-single to low-double digits.
The Wilson Sonsini team that advised Sirius on patent matters related to the transaction was led by Minyoung Shin and included Mike Hostetler, Hee Min Noh, Jen Zeng, and Tiara Wong.
For more information, please see the companies’ news release. Additional coverage is available in Fierce Biotech and BioSpace.
Under the terms of the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to Sirius. The companies will jointly develop SRSD107—a next-generation, long-acting Factor XI (FXI) siRNA for the treatment of thromboembolic disorders—under a 50-50 cost and profit-sharing structure. CRISPR Therapeutics will lead commercialization in the U.S., while Sirius will be responsible for commercialization in Greater China. Additionally, CRISPR Therapeutics will have the option to nominate up to two siRNA targets for research and development. For each target, CRISPR Therapeutics will fund research and retain opt-in rights to lead clinical development and commercialization. Sirius will be eligible to receive milestone payments, as well as tiered royalties ranging from high-single to low-double digits.
The Wilson Sonsini team that advised Sirius on patent matters related to the transaction was led by Minyoung Shin and included Mike Hostetler, Hee Min Noh, Jen Zeng, and Tiara Wong.
For more information, please see the companies’ news release. Additional coverage is available in Fierce Biotech and BioSpace.
Client Highlights
5.12.25
Firm Advises HAYA Therapeutics on Patent Matters Related to $65 Million Series A Financing
On May 8, 2025, HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has raised $65 million in Series A funding. The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly, ATHOS, +ND Capital, Alexandria Venture Investments, and LifeLink Ventures, with additional support from existing investors. Wilson Sonsini Goodrich & Rosati advised HAYA Therapeutics on patent matters related to the transaction.
Client Highlights
5.12.25
Firm Advises Sirius Therapeutics on Patent Matters Related to $50 Million Series B2 Financing
On May 9, 2025, biotechnology company Sirius Therapeutics announced that it has successfully completed nearly $50 million Series B2 financing. A corporate venture capital firm led the financing round and was joined by new investor BioTrack Capital and existing investors OrbiMed, Creacion Ventures, and Hankang Capital. Wilson Sonsini Goodrich & Rosati advised Sirius Therapeutics on patent matters related to the transaction.
Client Highlights
9.05.24
Wilson Sonsini Advises HAYA Therapeutics on Patent Matters Related to Collaboration with Eli Lilly
On September 4, 2024, HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. Wilson Sonsini Goodrich & Rosati advised HAYA on patent matters related to the transaction.
Client Highlights
10.25.23
Wilson Sonsini Advises DermBiont on $35.2 Million Series B Financing
On October 24, 2023, DermBiont, a clinical-stage biotechnology company advancing targeted topical therapeutics for the treatment of dermatological indications, announced a $35.2 million Series B financing. The financing was led by new institutional investor Double Point Ventures, and included continued support from Viking Global Investors, Civilization Ventures, Olive Tree Capital, and others. Wilson Sonsini Goodrich & Rosati provided IP and corporate counsel to DermBiont in the transaction.
The proceeds from the financing will be used to advance the clinical development of two drugs: SM-020, a topical novel AKT kinase inhibitor for the treatment of seborrheic keratoses (SKs), and SM-030, a topical novel PKC-beta inhibitor for the treatment of melasma and other hyperpigmentation disorders of the skin. They are expected to fund the company through end of its Phase 2 meetings with the U.S. Food and Drug Administration (FDA), which are expected in the second half of 2024 for both programs.
Wilson Sonsini has represented DermBiont on IP matters since the company’s inception, and the patent team that advised on the Series B included Matt Bresnahan, Alicia Umpierre, Dalton Case, and Tiara Wong. The Wilson Sonsini corporate team that advised on the transaction included Jason Skolnik, Dani Glazer Signaigo, and Leila Purqurian.
For more information, please see DermBiont’s news release.
The proceeds from the financing will be used to advance the clinical development of two drugs: SM-020, a topical novel AKT kinase inhibitor for the treatment of seborrheic keratoses (SKs), and SM-030, a topical novel PKC-beta inhibitor for the treatment of melasma and other hyperpigmentation disorders of the skin. They are expected to fund the company through end of its Phase 2 meetings with the U.S. Food and Drug Administration (FDA), which are expected in the second half of 2024 for both programs.
Wilson Sonsini has represented DermBiont on IP matters since the company’s inception, and the patent team that advised on the Series B included Matt Bresnahan, Alicia Umpierre, Dalton Case, and Tiara Wong. The Wilson Sonsini corporate team that advised on the transaction included Jason Skolnik, Dani Glazer Signaigo, and Leila Purqurian.
For more information, please see DermBiont’s news release.